LCTX יחס הלוואות לטווח ארוך להון Lineage Corp

Lineage Cell Therapeutics (LCTX) holds a high status in the field of tissue regeneration, yet the absence of profitable products creates a financial dependence on external grants. The price indicator on this chart reflects the asset's dynamics, with a metric of 0.02. Company management is focused on developing cell-based methods to combat vision loss and expanding the functionality of its technological base.

By developing a cell therapy platform to combat neurological and ophthalmological pathologies, Lineage Cell Therapeutics (LCTX) diversifies risk through a broad research portfolio. The current value of 0.02 reflects the ratio of long-term loans to the market value of equity, allowing investors to assess financial leverage and the stability of the capital structure regarding long-term liabilities relative to the company's equity.